Intuitive Surgical (NASDAQ:ISRG) Price Target Raised to $375.00 at Jefferies Financial Group

Intuitive Surgical (NASDAQ:ISRG) had its price objective boosted by stock analysts at Jefferies Financial Group from $365.00 to $375.00 in a report released on Friday, Benzinga reports. The firm presently has a “hold” rating on the medical equipment provider’s stock. Jefferies Financial Group’s price objective would suggest a potential upside of 0.64% from the company’s current price.

A number of other analysts have also recently commented on the company. Citigroup upped their price target on Intuitive Surgical from $428.00 to $462.00 and gave the company a “buy” rating in a research note on Wednesday, April 3rd. Wells Fargo & Company upped their price target on Intuitive Surgical from $363.00 to $416.00 and gave the company an “overweight” rating in a research note on Friday, January 19th. Truist Financial upped their price target on Intuitive Surgical from $390.00 to $435.00 and gave the company a “buy” rating in a research note on Wednesday, January 24th. Raymond James upped their price target on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research note on Thursday, January 25th. Finally, Piper Sandler boosted their price objective on Intuitive Surgical from $325.00 to $425.00 and gave the company an “overweight” rating in a research report on Wednesday, January 24th. Six analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $378.48.

Intuitive Surgical Trading Down 0.4 %

Shares of NASDAQ:ISRG opened at $372.63 on Friday. The stock has a market capitalization of $132.08 billion, a P/E ratio of 74.08, a P/E/G ratio of 5.81 and a beta of 1.36. Intuitive Surgical has a 1-year low of $254.85 and a 1-year high of $403.76. The business has a 50-day moving average price of $387.27 and a two-hundred day moving average price of $342.60.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The company’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period in the previous year, the business posted $1.00 EPS. As a group, equities analysts predict that Intuitive Surgical will post 4.93 EPS for the current year.

Insider Activity

In other news, VP Marshall Mohr sold 108,790 shares of the stock in a transaction that occurred on Wednesday, February 28th. The stock was sold at an average price of $385.08, for a total value of $41,892,853.20. Following the completion of the sale, the vice president now owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The transaction was disclosed in a legal filing with the SEC, which is available at this link. In other Intuitive Surgical news, EVP Myriam Curet sold 4,318 shares of the firm’s stock in a transaction on Friday, January 26th. The stock was sold at an average price of $370.15, for a total transaction of $1,598,307.70. Following the completion of the sale, the executive vice president now owns 189 shares of the company’s stock, valued at approximately $69,958.35. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Marshall Mohr sold 108,790 shares of the firm’s stock in a transaction on Wednesday, February 28th. The shares were sold at an average price of $385.08, for a total value of $41,892,853.20. Following the sale, the vice president now directly owns 26,877 shares of the company’s stock, valued at approximately $10,349,795.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 248,418 shares of company stock valued at $95,927,097. 0.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Intuitive Surgical

A number of hedge funds and other institutional investors have recently modified their holdings of ISRG. RB Capital Management LLC lifted its holdings in shares of Intuitive Surgical by 4.4% during the first quarter. RB Capital Management LLC now owns 1,735 shares of the medical equipment provider’s stock worth $523,000 after buying an additional 73 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Intuitive Surgical by 0.6% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 946,709 shares of the medical equipment provider’s stock worth $285,603,000 after buying an additional 5,233 shares in the last quarter. Baird Financial Group Inc. lifted its holdings in shares of Intuitive Surgical by 2.3% during the first quarter. Baird Financial Group Inc. now owns 21,089 shares of the medical equipment provider’s stock worth $6,362,000 after buying an additional 481 shares in the last quarter. Brown Brothers Harriman & Co. increased its position in shares of Intuitive Surgical by 576.7% in the first quarter. Brown Brothers Harriman & Co. now owns 406 shares of the medical equipment provider’s stock worth $122,000 after purchasing an additional 346 shares during the period. Finally, Covestor Ltd increased its position in shares of Intuitive Surgical by 50.4% in the first quarter. Covestor Ltd now owns 418 shares of the medical equipment provider’s stock worth $126,000 after purchasing an additional 140 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.